{"entity":{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","aka":["Faron","AIM:FARN"],"tldr":"Faron Pharmaceuticals is a Finnish biotech whose antibody bexmarilimab re-programmes immunosuppressive macrophages, with early activity in myelodysplastic syndromes and leukaemia.","summary":"Faron Pharmaceuticals, based in Turku and listed in London and Helsinki, develops immunotherapies that act on the myeloid arm of the immune system. Its lead candidate, bexmarilimab (FP-1305), binds Clever-1 on tumour-associated macrophages and converts them from an immunosuppressive to an immune-activating state. The BEXMAB study combines it with azacitidine in myelodysplastic syndromes and acute myeloid leukaemia; earlier MATINS trials tested it in solid tumours.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.faron.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["bexmarilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Turku","country":"FI","companyType":"biotech","website":"https://www.faron.com/","ticker":"AIM:FARN","stage":"public","investors":[],"funding":[]},"route":"/companies/faron-pharmaceuticals/","neighbours":{"drug":[{"id":"bexmarilimab","kind":"drug","name":"Bexmarilimab","route":"/drugs/bexmarilimab/"}]}}